Avoro Capital Advisors LLC Tricida, Inc. Transaction History

Avoro Capital Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $5.14 Million - $16.2 Million	-600,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $16.2 Million - $24.1 Million	-765,000 Reduced 56.04%	600,000 $16.5 Million
Q1 2020 May 15, 2020	SELL	$18.43 - $38.04 $3.59 Million - $7.42 Million	-195,000 Reduced 12.5%	1,365,000 $30 Million
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $18.9 Million - $28 Million	-640,000 Reduced 29.09%	1,560,000 $58.9 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $15.6 Million - $19.7 Million	500,000 Added 29.41%	2,200,000 $86.8 Million
Q1 2019 May 15, 2019	SELL	$19.96 - $38.62 $998,000 - $1.93 Million	-50,000 Reduced 2.86%	1,700,000 $65.7 Million
Q4 2018 Feb 14, 2019	SELL	$23.57 - $32.33 $506,755 - $695,095	-21,500 Reduced 1.21%	1,750,000 $41.3 Million
Q3 2018 Nov 14, 2018	BUY	$22.5 - $39.35 $15.2 Million - $26.6 Million	675,736 Added 61.67%	1,771,500 $54.1 Million
Q2 2018 Aug 14, 2018	BUY	$26.0 - $29.9 $28.5 Million - $32.8 Million	1,095,764 New	1,095,764 $32.8 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.